Supplemental Table 1. Comparison of DRVVT normalized ratio stratified by INR in patients treated with warfarin

Undiluted Plasma / Diluted Plasma
INR (Number) / Screen ratio* / Confirm ratio* / Screen/Confirm ratio* / Screen ratio* / Confirm ratio* / Screen/Confirm ratio*
< 1.5 (66) / 1.29 ± 0.26 / 1.21 ± 0.17 / 1.07 ± 0.11 / 1.14 ± 0.14 / 1.04 ± 0.10 / 1.05 ± 0.05
1.53.0 (139) / 1.58 ± 0.39 / 1.35 ± 0.11 / 1.10 ± 0.18 / 1.18 ± 0.30 / 1.06 ± 0.07 / 1.17 ± 0.25
> 3.0 (37) / 1.88 ± 0.42 / 1.47 ± 0.21 / 1.27 ± 0.18 / 1.16 ± 0.08 / 1.11 ± 0.09 / 1.15 ± 0.07

INR, international normalized ratio; Undiluted Plasma, measured directly on a patient sample

Diluted Plasma, measured on 1:1 mixture of normal pooled plasma and patient plasma sample

* mean ± standard deviation

Screen/confirm ratio, Screen ratio/confirm ratio, DRVVT used with paired screen and confirmation reagents.

Supplemental Table 2. Comparison of the dilute Russell viper venom time test methods and the APTT

Mixing test and STACLOT LA*
DRVVT-R†(ISTH) / (+) / (-) / Total
(+) / 38 / 15 / 53
(-) / 0 / 152 / 152
Total / 38 / 167 / 205
Mixing test and STACLOT LA*
DRVVT-R††(BCSH) / (+) / (-) / Total
(+) / 37 / 49 / 86
(-) / 1 / 155 / 156
Total / 38 / 204 / 242
Mixing test and STACLOT LA*
DRVVT-R†††(CLSI) / (+) / (-) / Total
(+) / 37 / 52 / 89
(-) / 1 / 152 / 153
Total / 38 / 204 / 242

LA; Lupus anticoagulant; LA judged based on the APTT method. DRVVT-R, dilute Russell’s viper venom time ratio: the ratio of the dilute Russell’s viper venom time screen reagent to the dilute Russell’s viper venom time confirmation reagent measurement using only patient plasma

†Presence of lupus anticoagulant was diagnosed at a cut-off value of ≥ 1.22, based on the ISTH guidelines.

††Presence of lupus anticoagulant was diagnosed at a cut-off value of ≥ 1.20 or more, based on the BCSH guidelines.

†††Presence of lupus anticoagulant was diagnosed at a cut-off value of ≥ 1.19, based on the CLSI guidelines.

* The measurement result of a mixing test and the APTT method

Supplemental Table 3. Comparison of clotting factor activity stratified by international normalized ratio (INR) in patients treated with warfarin

INR (Number) / Undiluted patient plasma＊ / Diluted with NPP＊
Factor II / Factor X / Factor II / Factor X
< 1.0 (34) / 111.1 ± 9.3 / 102.0 ± 12.8 / 108.2 ± 9.6 / 104.6 ± 10.3
< 1.5 (66) / 50.1 ± 26.5 / 30.8 ± 19.7 / 75.8 ± 11.6 / 72.3 ± 11.4
1.53.0 (139) / 29.5 ± 10.4 / 18.5 ± 10.5 / 72.8 ± 9.0 / 69.2 ± 9.1
> 3.0 (37) / 14.2 ± 4.1 / 9.7 ± 2.48 / 50.3 ± 13.3 / 56.9 ± 10.6

INR, international normalized ratio; NPP, normal pooled plasma;

Factor II, Coagulation factor II activity; Factor X, Coagulation factor X activity;

＊, Mean ± Standard deviation